23
Participants
Start Date
June 18, 2020
Primary Completion Date
May 2, 2022
Study Completion Date
May 2, 2022
Isatuximab SAR650984
"Pharmaceutical form: Solution for infusion~Route of administration: Intravenous"
Acetaminophen (paracetamol) or equivalent
"Pharmaceutical form: Tablets~Route of administration: Oral"
Ranitidine or equivalent
"Pharmaceutical form: Solution~Route of administration: Intravenous"
Diphenhydramine or equivalent
"Pharmaceutical form: Solution~Route of administration: Intravenous"
Methylprednisolone or equivalent
"Pharmaceutical form: Solution~Route of administration: Intravenous"
Montelukast or equivalent
"Pharmaceutical form: Tablets~Route of administration: Oral"
Investigational Site Number :8400002, New York
Investigational Site Number :8400001, Rochester
Investigational Site Number :8400004, Houston
Investigational Site Number :8400003, San Francisco
Investigational Site Number :7240002, Barcelona
Investigational Site Number :7240001, L'Hospitalet de Llobregat
Lead Sponsor
Sanofi
INDUSTRY